{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "24550227",
        "21670202",
        "22150006",
        "26200345",
        "22077063"
      ],
      "tumorType":{
        "children":{},
        "code":"CLLSLL",
        "color":"LimeGreen",
        "id":533,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx2",
      "pmids":[
        "19794079",
        "16826225",
        "15472075",
        "16707600"
      ],
      "tumorType":{
        "children":{},
        "code":"",
        "color":"LimeGreen",
        "id":941,
        "level":0,
        "mainType":{
          "id":null,
          "name":"T-Lymphoblastic Leukemia/Lymphoma",
          "tumorForm":"LIQUID"
        },
        "name":"",
        "parent":null,
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"NOTCH1, a transmembrane receptor and transcription factor, can function as both an oncogene and tumor suppressor.",
  "highestDiagnosticImplicationLevel":"LEVEL_Dx2",
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":"LEVEL_Px3",
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"04/13/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "22006338",
        "21798897",
        "24651013",
        "21798893"
      ]
    },
    "description":"NOTCH1 truncating mutations include recurrent nonsense, frameshift or splice-site mutations in NOTCH1 leading to truncation and functional inactivation of the NOTCH1 protein (PMID: 24651013, 22006338). These mutations typically occur upstream of the intracellular transactivation domain (TAD) of NOTCH1, most often in the N-terminal extracellular epidermal growth factor (EGF) repeats (amino acids 1-1444), or less commonly in intracellular domains (amino acids 1735-2250). A variety of solid tumors, most commonly squamous cell carcinomas from various sites, exhibit these mutations (PMID: 21798897, 21798893); however additional studies are required to fully understand the functional consequences of these mutations.",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Px3",
      "pmids":[
        "20861909",
        "16707600",
        "20861920"
      ],
      "tumorType":{
        "children":{},
        "code":"",
        "color":"LimeGreen",
        "id":941,
        "level":0,
        "mainType":{
          "id":null,
          "name":"T-Lymphoblastic Leukemia/Lymphoma",
          "tumorForm":"LIQUID"
        },
        "name":"",
        "parent":null,
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "prognosticSummary":"",
  "query":{
    "alteration":"P1731Rfs*67",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":4851,
    "hgvs":"9:g.136502466del",
    "hugoSymbol":"NOTCH1",
    "id":null,
    "proteinEnd":1730,
    "proteinStart":1730,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The NOTCH1 P1731Rfs*67 mutation is known to be oncogenic.",
  "vus":false
}